Aequus Pharmaceuticals Inc. (AQS.V)
| Previous Close | 0.0700 |
| Open | 0.0700 |
| Bid | 0.0650 x 0 |
| Ask | 0.0850 x 0 |
| Day's Range | 0.0700 - 0.0700 |
| 52 Week Range | 0.0650 - 0.1600 |
| Volume | |
| Avg. Volume | 11,979 |
| Market Cap | 9.284M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0130 |
| Earnings Date | Jul 04, 2022 - Jul 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.52 |
- GlobeNewswire
Aequus Provides General Update and Reports Record 2021 Financial Results
Also reports Financial Results for the 3 months ended March 31, 2022 VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a sales force that currently markets third party or exclusively licensed products for which the Company receives revenues from direct product sales and profit share arrangements, today reported financial results for the year ended December 31,
- GlobeNewswire
Aequus Provides Update on Delay in Filing Annual Financial Statements
VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that further to its news release on May 6, 2022 and May 26, 2022, the filing of its audited annual financial statements for the fiscal year ended December 31, 2021 and the related management’s discussion and analysis (collectively, the “Annual Disclosure”) as well at the financial statements for the three months ended March 31, 2022 and the r
